| JANDOVA, M., P. SPONER, D. VOKURKOVA, P. O. BAUER, A. FILIPOVA, S. FILIP and P. MERICKA. NEW CRYOPRESERVATION TECHNOLOGY OF HMSCS: FIRST PRECLINICAL RESULTS USING DMSO-CONTAINING MEDIUM. CryoLetters. LONDON: CRYO LETTERS, 2020, vol. 41, No 1, p. 50-56. ISSN 0143-2044. |
Other formats:
BibTeX
LaTeX
RIS
@article{1807986,
author = {Jandova, M. and Sponer, P. and Vokurkova, D. and Bauer, P. O. and Filipova, A. and Filip, S. and Mericka, P.},
article_location = {LONDON},
article_number = {1},
keywords = {mesenchymal stem cells; advanced therapy medicinal product; dimethyl sulfoxide; cryopreservation},
language = {eng},
issn = {0143-2044},
journal = {CryoLetters},
title = {NEW CRYOPRESERVATION TECHNOLOGY OF HMSCS: FIRST PRECLINICAL RESULTS USING DMSO-CONTAINING MEDIUM},
url = {https://www.webofscience.com/wos/woscc/full-record/WOS:000527407900009},
volume = {41},
year = {2020}
}
TY - JOUR
ID - 1807986
AU - Jandova, M. - Sponer, P. - Vokurkova, D. - Bauer, P. O. - Filipova, A. - Filip, S. - Mericka, P.
PY - 2020
TI - NEW CRYOPRESERVATION TECHNOLOGY OF HMSCS: FIRST PRECLINICAL RESULTS USING DMSO-CONTAINING MEDIUM
JF - CryoLetters
VL - 41
IS - 1
SP - 50-56
EP - 50-56
PB - CRYO LETTERS
SN - 01432044
KW - mesenchymal stem cells
KW - advanced therapy medicinal product
KW - dimethyl sulfoxide
KW - cryopreservation
UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000527407900009
N2 - BACKGROUND: Human mesenchymal stem cells (hMSCs) have tremendous potential in regenerative medicine, making it desirable to cryopreserve and bank them to increase their access and availability. OBJECTIVE: This research is part of a clinical trial performed on six patients that aimed to use advanced therapy medicinal products (ATMPs) based on hMSCs in patients undergoing repeated total hip replacement. MATERIALS AND METHODS: To compare the characteristics of fresh and frozen hMSCs, we used the trypan blue exclusion test (cell viability), flow cytometry (cell viability and phenotyping), sterility determinations and the clonogenic assay of cell proliferation. RESULTS: Cryopreserved hMSCs showed good quality parameters after thawing in comparison with fresh hMSCs in suspension. When using a medium containing dimethyl sulfoxide (DMSO), the viability was higher than 90% in all cases. The cell purity determined by flow cytometry was also acceptable. CONCLUSION: These initial results show that the prepared cryopreserved ATMP exhibited good viability and phenotype characteristics.
ER -
JANDOVA, M., P. SPONER, D. VOKURKOVA, P. O. BAUER, A. FILIPOVA, S. FILIP and P. MERICKA. NEW CRYOPRESERVATION TECHNOLOGY OF HMSCS: FIRST PRECLINICAL RESULTS USING DMSO-CONTAINING MEDIUM. \textit{CryoLetters}. LONDON: CRYO LETTERS, 2020, vol.~41, No~1, p.~50-56. ISSN~0143-2044.
|
